Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) was upgraded by research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a research note issued on Saturday, Wall Street Zen reports.
Other equities analysts also recently issued research reports about the stock. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Arcturus Therapeutics in a research note on Thursday, October 15th. BTIG Research dropped their price target on shares of Arcturus Therapeutics from $23.00 to $20.00 and set a "buy" rating on the stock in a research report on Thursday, September 24th. Leerink Partners increased their price objective on shares of Arcturus Therapeutics from $13.00 to $19.00 and gave the company an "outperform" rating in a research note on Friday, October 9th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Arcturus Therapeutics in a research note on Thursday, September 24th. Finally, Citigroup raised shares of Arcturus Therapeutics from a "neutral" rating to a "buy" rating and lifted their price objective for the stock from $8.00 to $20.00 in a research report on Thursday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Arcturus Therapeutics has an average rating of "Moderate Buy" and an average target price of $22.29.
Read Our Latest Analysis on Arcturus Therapeutics
Arcturus Therapeutics Price Performance
Shares of Arcturus Therapeutics stock opened at $10.35 on Friday. The firm has a 50 day simple moving average of $13.10 and a 200 day simple moving average of $9.05. Arcturus Therapeutics has a fifty-two week low of $5.50 and a fifty-two week high of $17.96.
Arcturus Therapeutics (NASDAQ:ARCT - Get Free Report) last released its quarterly earnings results on Thursday, November 5th. The biotechnology company reported ($0.26) EPS for the quarter, topping analysts' consensus estimates of ($0.69) by $0.43. The company had revenue of $18.30 million for the quarter, compared to analyst estimates of $8.00 million. Arcturus Therapeutics had a negative return on equity of 46.54% and a negative net margin of 317.62%. On average, analysts expect that Arcturus Therapeutics will post -3.48 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Allspring Global Investments Holdings LLC raised its holdings in Arcturus Therapeutics by 4.1% in the 3rd quarter. Allspring Global Investments Holdings LLC now owns 28,782 shares of the biotechnology company's stock valued at $394,000 after acquiring an additional 1,131 shares during the last quarter. Alps Advisors Inc. boosted its holdings in shares of Arcturus Therapeutics by 29.6% during the 3rd quarter. Alps Advisors Inc. now owns 37,390 shares of the biotechnology company's stock worth $512,000 after purchasing an additional 8,545 shares during the last quarter. Green Alpha Advisors LLC boosted its holdings in shares of Arcturus Therapeutics by 7.9% during the 3rd quarter. Green Alpha Advisors LLC now owns 29,234 shares of the biotechnology company's stock worth $400,000 after purchasing an additional 2,143 shares during the last quarter. Versant Capital Management Inc boosted its holdings in shares of Arcturus Therapeutics by 648.6% during the 3rd quarter. Versant Capital Management Inc now owns 3,032 shares of the biotechnology company's stock worth $42,000 after purchasing an additional 2,627 shares during the last quarter. Finally, Squarepoint Ops LLC grew its position in shares of Arcturus Therapeutics by 264.8% in the second quarter. Squarepoint Ops LLC now owns 50,253 shares of the biotechnology company's stock valued at $338,000 after purchasing an additional 36,479 shares in the last quarter. Institutional investors own 94.54% of the company's stock.
About Arcturus Therapeutics
(
Get Free Report)
Arcturus Therapeutics Holdings Inc is a biotechnology company headquartered in San Diego, California, focused on developing medicines based on messenger RNA (mRNA) and other RNA technologies. The company's platform includes LUNAR, a lipid-mediated delivery system designed to transport nucleic acids into cells, as well as technologies for producing and administering mRNA and self-amplifying RNA.
The company's development programs address infectious diseases and rare genetic disorders. Arcturus has developed KOSTAIVE, a self-amplifying mRNA COVID-19 vaccine known as ARCT-154, in collaboration with CSL.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Arcturus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arcturus Therapeutics wasn't on the list.
While Arcturus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.